| Indication . | 1990–1993 (n = 22) . | 1994–1997 (n = 30) . | 1998–2001 (n = 41) . | 2002–2005 (n = 59) . | 2006–2009 (n = 66) . | 2010–2014 (n = 75) . |
|---|---|---|---|---|---|---|
| Pulmonary fibrosis | 18% (n = 4) | 0% (n = 0) | 17% (n = 7) | 5% (n = 3) | 20% (n = 13) | 15% (n = 11) |
| Cystic fibrosis | 9% (n = 2) | 6% (n = 2) | 20% (n = 8) | 17% (n = 10) | 21% (n = 14) | 24% (n = 18) |
| Pulmonary hypertension | 36% (n = 8) | 27% (n = 8) | 12% (n = 5) | 12% (n = 7) | 6% (n = 4) | 9% (n = 7) |
| ReTx | 0% (n = 0) | 0% (n = 0) | 2% (n = 1) | 7% (n = 4) | 5% (n = 3) | 9% (n = 7) |
| COPD | 14% (n = 3) | 20% (n = 6) | 17% (n = 7) | 30% (n = 18) | 29% (n = 19) | 18% (n = 14) |
| AAT1 | 23% (n = 5) | 30% (n = 9) | 20% (n = 8) | 22% (n = 13) | 13% (n = 9) | 15% (n = 11) |
| Othera | 0% (n = 0) | 17% (n = 5) | 12% (n = 5) | 7% (n = 4) | 6% (n = 4) | 10% (n = 7) |
| Indication . | 1990–1993 (n = 22) . | 1994–1997 (n = 30) . | 1998–2001 (n = 41) . | 2002–2005 (n = 59) . | 2006–2009 (n = 66) . | 2010–2014 (n = 75) . |
|---|---|---|---|---|---|---|
| Pulmonary fibrosis | 18% (n = 4) | 0% (n = 0) | 17% (n = 7) | 5% (n = 3) | 20% (n = 13) | 15% (n = 11) |
| Cystic fibrosis | 9% (n = 2) | 6% (n = 2) | 20% (n = 8) | 17% (n = 10) | 21% (n = 14) | 24% (n = 18) |
| Pulmonary hypertension | 36% (n = 8) | 27% (n = 8) | 12% (n = 5) | 12% (n = 7) | 6% (n = 4) | 9% (n = 7) |
| ReTx | 0% (n = 0) | 0% (n = 0) | 2% (n = 1) | 7% (n = 4) | 5% (n = 3) | 9% (n = 7) |
| COPD | 14% (n = 3) | 20% (n = 6) | 17% (n = 7) | 30% (n = 18) | 29% (n = 19) | 18% (n = 14) |
| AAT1 | 23% (n = 5) | 30% (n = 9) | 20% (n = 8) | 22% (n = 13) | 13% (n = 9) | 15% (n = 11) |
| Othera | 0% (n = 0) | 17% (n = 5) | 12% (n = 5) | 7% (n = 4) | 6% (n = 4) | 10% (n = 7) |
aIncludes bronchiectasis, sarcoidosis, bronchioalveolar cancer, silicosis, ARDS and GVHD.
ReTx: retransplantation; COPD: chronic obstructive pulmonary disease; AAT1: α1-antitrypsin deficiency; GVHD: graft-vs-host disease.
| Indication . | 1990–1993 (n = 22) . | 1994–1997 (n = 30) . | 1998–2001 (n = 41) . | 2002–2005 (n = 59) . | 2006–2009 (n = 66) . | 2010–2014 (n = 75) . |
|---|---|---|---|---|---|---|
| Pulmonary fibrosis | 18% (n = 4) | 0% (n = 0) | 17% (n = 7) | 5% (n = 3) | 20% (n = 13) | 15% (n = 11) |
| Cystic fibrosis | 9% (n = 2) | 6% (n = 2) | 20% (n = 8) | 17% (n = 10) | 21% (n = 14) | 24% (n = 18) |
| Pulmonary hypertension | 36% (n = 8) | 27% (n = 8) | 12% (n = 5) | 12% (n = 7) | 6% (n = 4) | 9% (n = 7) |
| ReTx | 0% (n = 0) | 0% (n = 0) | 2% (n = 1) | 7% (n = 4) | 5% (n = 3) | 9% (n = 7) |
| COPD | 14% (n = 3) | 20% (n = 6) | 17% (n = 7) | 30% (n = 18) | 29% (n = 19) | 18% (n = 14) |
| AAT1 | 23% (n = 5) | 30% (n = 9) | 20% (n = 8) | 22% (n = 13) | 13% (n = 9) | 15% (n = 11) |
| Othera | 0% (n = 0) | 17% (n = 5) | 12% (n = 5) | 7% (n = 4) | 6% (n = 4) | 10% (n = 7) |
| Indication . | 1990–1993 (n = 22) . | 1994–1997 (n = 30) . | 1998–2001 (n = 41) . | 2002–2005 (n = 59) . | 2006–2009 (n = 66) . | 2010–2014 (n = 75) . |
|---|---|---|---|---|---|---|
| Pulmonary fibrosis | 18% (n = 4) | 0% (n = 0) | 17% (n = 7) | 5% (n = 3) | 20% (n = 13) | 15% (n = 11) |
| Cystic fibrosis | 9% (n = 2) | 6% (n = 2) | 20% (n = 8) | 17% (n = 10) | 21% (n = 14) | 24% (n = 18) |
| Pulmonary hypertension | 36% (n = 8) | 27% (n = 8) | 12% (n = 5) | 12% (n = 7) | 6% (n = 4) | 9% (n = 7) |
| ReTx | 0% (n = 0) | 0% (n = 0) | 2% (n = 1) | 7% (n = 4) | 5% (n = 3) | 9% (n = 7) |
| COPD | 14% (n = 3) | 20% (n = 6) | 17% (n = 7) | 30% (n = 18) | 29% (n = 19) | 18% (n = 14) |
| AAT1 | 23% (n = 5) | 30% (n = 9) | 20% (n = 8) | 22% (n = 13) | 13% (n = 9) | 15% (n = 11) |
| Othera | 0% (n = 0) | 17% (n = 5) | 12% (n = 5) | 7% (n = 4) | 6% (n = 4) | 10% (n = 7) |
aIncludes bronchiectasis, sarcoidosis, bronchioalveolar cancer, silicosis, ARDS and GVHD.
ReTx: retransplantation; COPD: chronic obstructive pulmonary disease; AAT1: α1-antitrypsin deficiency; GVHD: graft-vs-host disease.
This PDF is available to Subscribers Only
View Article Abstract & Purchase OptionsFor full access to this pdf, sign in to an existing account, or purchase an annual subscription.
